References (2022)

Canfell K, Saville M, Caruana M, et al. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. BMJ open 2018; 8(1): e016700.

World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Available at: https://www.who.int/ publications/i/item/9789240014107.

Australian Institute of Health and Welfare. National Cervical Screening Program monitoring report 2021. Cancer Series 134. Cat. no: CAN 141 Canberra: AIHW; 2021.

Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 2019; 4(1): e19-e27.
5. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA). ABS Catalogue no.

Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA). ABS Catalogue no. 2033.0.55.001. Canberra, 2013. Available at: https://www.abs.gov.au/AUSSTATS/abs@.nsf/ DetailsPage/2033.0.55.0012016?OpenDocument.

Australian Bureau of Statistics. 1270.0.55.006 - Australian Statistical Geography Standard (ASGS): Correspondences, July 2011 2012 2013. Statistical Area Level 2 2011 to Remoteness Area 2011, Postcode 2012 to Remoteness Area 2011]. Available at: https://www.abs.gov.au/ AUSSTATS/abs@.nsf/DetailsPage/1270.0.55.006July%20 2011?OpenDocument.

Australian Bureau of Statistics. 1270.0.55.001 - Australian Statistical Geography Standard (ASGS): Volume 1 - Main Structure and Greater Capital City Statistical Areas, July 2016 2016. Correspondence, 2011 Statistical Area Level 2 to 2016 Statistical Area Level 2]. Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/1270.0.55.001July%202016?OpenDocument

Hall MT, Simms KT, Lew JB, et al. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. PLoS One 2018; 13(2): e0185332.

Lei J, Ploner A, Elfstrom KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine 2020; 383(14): 1340-8.

Brisson M, Benard E, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1(1): e8-e17.

Australian Institute of Health and Welfare (AIHW) 2022 Cancer Data in Australia; Canberra, 2022 Available at: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/about

Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 2020; 395(10224): 591-603 .

Victorian Cancer Registry. Cancer in Victoria 2020. Cancer Council Victoria. Melbourne, Victoria. 2021 Available at: https://www.cancervic.org.au/downloads/cec/cancer-in-vic/Cancer-in-Victoria-statistics-and-trends-2020.pdf

Australian Institute of Health and Welfare. National Cervical Screening Program data dictionary: version 1.1. Catalogue number CAN 146 Canberra: AIHW; 2022.

Australian Bureau of Statistics. Australia 2001 Standard Population for Use in Age-Standardisation. 2003. Available at: https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Mar%202013?OpenDocument

Australian Institute of Health and Welfare 2019. Cervical screening in Australia 2019. Cancer series no. 123. Cat. no. CAN 124. Canberra: AIHW

Li M, Roder D, Whop LJ, et al. Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993-2016. Journal of Medical Screening 2019; 26(2): 104-12.

Whop LJ, Baade P, Garvey G, et al. Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000-2011. PLoS One 2016; 11(4): e0150473.

Zhang X, Condon J. Cancer screening in the Northern Territory 2019. Department of Health, Darwin, 2019. Available at: https://digitallibrary.health.nt.gov.au/prodjspui/handle/10137/7938

Brotherton JM, Hawkes D, Sultana F, et al. Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact. Vaccine 2019; 37(3): 412-6.

Machalek DA, Garland SM, Brotherton JML, et al. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. The Journal of Infectious Diseases 2018; 217(10): 1590-600.

Garland SM, Brotherton JM, Condon JR, et al. Human papillomavirus prevalence among indigenous and nonindigenous Australian women prior to a national HPV vaccination program. BMC Medicine 2011; 9: 104.

McGregor S, Saulo D, Brotherton JML, et al. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study. Vaccine 2018; 36(29): 4311-6.

Shilling, H, Garland, SM, et al. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction. Vaccine 2021, 39(34), 4856–4863.

Simms KT, Steinberg J, Caruana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncology 2019; 20(3): 394-407.

World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations. Weekly epidemiological record 2022; 97, 261–276.

Bruni L, Saura-Lazaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 20102019. Preventive Medicine 2020: 106399.

Brisson M, Benard E, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1(1): e8-e17.

Brotherton JM, Budd A, Rompotis C, et al. Is one dose of human papillomavirus vaccine as effective as three?:  A national cohort analysis. Papillomavirus Research 2019; 8: 100177.

Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022 Jun;1(5):EVIDoa2100056.

Markowitz LE, Drolet M, Lewis RM,  et al. Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs. Vaccine. 2022 Sep 2;40(37):5413-5432.

Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low income and lower-middle-income countries. Lancet 2020; 395(10224): 575-90.

Burger EA, Smith MA, Killen J, et al. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health, 2020. 5(4):  p. e213-e222.

Victorian Cervical Cytology Registry Annual Statistical Report 2015. Melbourne, Victoria. Victorian Cervical Cytology Registry Dec 2017. Available at: https://www.vcs.org.au/wp-content/uploads/2019/07/17030_VCS_StatsReport15_ART.3.pdf

Victorian Cervical Cytology Registry Annual Statistical Report 2014. Melbourne, Victoria. Victorian Cervical Cytology Registry. Available at: https://www.vcs.org.au/wp-content/uploads/2019/07/VCCR_StatisticsReport_2014_Digital_FinalApproved.pdf

Victorian Cervical Cytology Registry Annual Statistical Report 2013. Melbourne, Victoria. Victorian Cervical Cytology Registry. Available at: https://www.vcs.org.au/wp-content/uploads/2019/07/VCS_StatisticsReport_2013_Web_SinglePages_Final.pdf

Australian Bureau of Statistics. Regional population by age and sex [Internet]. Canberra: ABS; 2021. Available at: https://www.abs.gov.au/statistics/people/population/regional-population-age-and-sex/latest-release.

Australian Bureau of Statistics. People Topics. 2022. [cited 2022 31st Aug 2022]; ERP by SA2 (ASGS 2016), Age and Sex, 2001 Onwards. Available from: https://explore.data.abs.gov.au/vis?pg=0&tm=erp%20sa2%202016&hc[dataflowId]=ERP_ASGS2016&df[ds]=PEOPLE_TOPICS&df[id]=ERP_ASGS2016&df[ag]=ABS&df[vs]=1.0.0&pd=2020%2C&dq=...STE%2BAUS..A&ly[cl]=AGE&ly[rw]=ASGS_2016%2CREGION_TYPE&ly[rs]=SEX%2CTIME_PERIOD

Australian Bureau of Statistics. SEIFA 2016 by Statistical Area 2 (SA2), 2018 [accessed 4th March 2021]; SEIFA 2016 by SA2. Available from http://stat.data.abs.gov.au/Index.aspx?DataSetCode=ABS_SEIFA_SA2

Smith M, Lew JB, Simms K, et al. Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program. Medical Journal of Australia 2016; 204(5): 194e1-e9.

Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. New England Journal of Medicine 2009; 360(14): 1385-94.

Whop LJ, Garvey G, Baade P, et al. The first comprehensive report on Indigenous Australian women’s inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000–2011). Cancer 2016; 122(10): 1560-9.

Dasgupta P, Cramb S, Baade P, et al. Regional variation in cervical cancer screening participation & outcomes among Aboriginal and non-Aboriginal Australian women: New South Wales (2006-2013). 2018. Available at:  https://apo.org.au/node/258511

WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240030824

Australian Institute of Health and Welfare 2018. Cervical screening in Australia 2018. Cat. no. CAN 111. Canberra: AIHW

Smith MA, Gertig D, Hall M, et al. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Services Research 2016; 16: 147.

Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia. [Version URL: https://wiki.cancer.org.au/australiawiki/index.php?oldid=214429].%20Available%20from:%20https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening

Whop LJ, Baade PD, Brotherton JM, et al. Time to clinical investigation for Indigenous and non-Indigenous Queensland women after a high-grade abnormal Pap smear, 2000-2009. Medical Journal of Australia 2017; 206(2): 73-7.

Smith MA, Sherrah M, Sultana F, et al. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ. 2022 Mar 30;376:e068582

Important changes to the National Cervical Screening Program's Clinical Guidelines pathway for women at intermediate risk. Department of Health and Aged Care, Australian Government. Jan 2021. Available at: https://www.health.gov.au/news/important-changes-to-the-national-cervical-screening-programs-clinical-guidelines-pathway-for-women-at-intermediate-risk

Canfell K, Saville M, Smith M, Brand A, Armstrong B, Hammond I and the Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. Oncogenic HPV types not 16/18. In: National Cervical Screening Program Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Last updated: July 2022. Available at: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/management-of-oncogenic-hpv-test-results/oncogenic-hpv-types-not-16-18

Lyndal Anderson, Selvan Pather, Gordon Wright, Ian Hammond, Marion Saville, and the Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. Treatment of high-grade squamous abnormalities. In: National Cervical Screening Program Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Last updated: July 2022 Available from: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/management-histologically-confirmed-high-grade-squamous-abnormalities/treatment-of-hsil

Walpole ET, Theile DE, Philpot S, et al, Cancer Alliance Queensland. Development and Implementation  of a Cancer Quality Index in Queensland, Australia:  A Tool for Monitoring Cancer Care. Journal of Oncology Practice 2019; 15:7, e636-e643.

Queensland Government. Queensland Cancer Quality Index: Indicators of safe, quality cancer care. Cancer care in public and private hospitals 2005-2019. Queensland Health, Brisbane, 2022. Available at https://cancerallianceqld.health.qld.gov.au/publications/

Queensland Government. Queensland Cancer Quality Index 2005-2019 Technical Appendix. Queensland Health, Brisbane, 2022. Available at https://cancerallianceqld.health.qld.gov.au/publications/

Department of Health and Human Services. Victorian Cancer Quality Index 2008–2015. Melbourne: State of Victoria, 2018.

Roder D, Davy M, Selva-Nayagam S, Gowda R, Paramasivam S, Adams J, et al. The value of local registry data for describing cervical cancer management and outcomes over three decades in Australia. Eur J Cancer Care (Engl). 2018;27(1).

Chiew KL, Chong S, Duggan KJ, Kaadan N, Vinod SK. Assessing guideline adherence and patient outcomes in cervical cancer. Asia Pac J Clin Oncol. 2017;13(5):e373-e80

Diaz A, Moore SP, Martin JH, et al. Factors associated with cancer-specific and overall survival among Indigenous and non-Indigenous gynecologic cancer patients in Queensland, Australia: a matched cohort study. International Journal of Gynecological Cancer 2015; 25(3): 542-7.

Diaz A, Baade PD, Valery PC, et al. Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012). PLoS One 2018; 13(5): e0196764.

Marcusson-Rababi B, Anderson K, Whop LJ, Butler T, Whitson N, Garvey G. Does gynaecological cancer care meet the needs of Indigenous Australian women? Qualitative interviews with patients and care providers. BMC Health Serv Res. 2019;19(1):606.

Anderson K, Diaz A, Parikh DR, et al. Accessibility of cancer treatment services for Indigenous Australians in the Northern Territory: perspectives of patients and care providers. BMC Health Services Research 2021; 21(1): 95.

National Cancer Expert Reference Group(NCERG). Optimal care pathway for women with cervical cancer 2020. Available at: https://www.cancervic.org.au/downloads/resources/booklets/Optimal%20care%20pathway%20for%20women%20with%20cervical%20cancer.pdf

Department of Gynaecological Oncology Annual Report 2019. Westmead Hospital, Western Sydney Local Health District. Available at: Avaiable at: https://www. anzgog.org.au/wp-content/uploads/2020/04/ANZGOG_AnnualReport2019_Final_Web_Apr2020.pdf

Gynaecology Tumour Stream 2016-2019 Triennial Report. March 2020. Melbourne, Victoria. Gynaecology Tumour Stream at Parkville, incorporating RWH, Peter Maccallum Cancer Centre, RMH and Sunshine Hospital.

Outcome Data Statistical Report 2016. Queensland Centre for Gynaecological Cancer. QLD Metro North. 2016. Available at: https://metronorth.health.qld.gov.au/wp-content/uploads/2017/11/cervical-cancer-report-2016.pdf

Heriot N, Brand A, Cohen P, et al. Developing an Australian multi-module clinical quality registry for gynaecological cancers: a protocol paper. BMJ Open 2020; 10(2): e034579

Australian Institute of Health and Welfare 2021. Cancer in Australia 2021. Cancer series no. 133. Cat. no. CAN 144. Canberra: AIHW.

Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023-75.

Australian Institute of Health and Welfare 2018. Analysis of cancer outcomes and screening behaviour for national cancer screening programs in Australia. Cancer series no. 111. Cat. no. CAN 115. Canberra: AIHW.

Australian Institute of Health and Welfare 2019. Analysis of cervical cancer and abnormality outcomes in an era of cervical screening and HPV vaccination in Australia. Cancer series no. 126. Cat. no. CAN 129. Canberra: AIHW. Available at: https://www.aihw.gov.au/reports/cancer-screening/analysis-of-cervical-cancer-and-abnormality/summary